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Abstract
Introduction
Optimizing outcome in biliary atresia (BA) requires timely diagnosis. Cholestasis is a pre-
senting feature of BA, as well as other diagnoses (Non-BA). Identification of clinical features
of neonatal cholestasis that would expedite decisions to pursue subsequent invasive testing
to correctly diagnose or exclude BA would enhance outcomes. The analytical goal was to
develop a predictive model for BA using data available at initial presentation.
Methods
Infants at presentation with neonatal cholestasis (direct/conjugated bilirubin >2 mg/dl
[34.2 μM]) were enrolled prior to surgical exploration in a prospective observational multi-
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centered study (PROBE–NCT00061828). Clinical features (physical findings, laboratory
results, gallbladder sonography) at enrollment were analyzed. Initially, 19 features were
selected as candidate predictors. Two approaches were used to build models for diagnosis
prediction: a hierarchical classification and regression decision tree (CART) and a logistic
regression model using a stepwise selection strategy.
Results
In PROBE April 2004-February 2014, 401 infants met criteria for BA and 259 for Non-BA.
Univariate analysis identified 13 features that were significantly different between BA and
Non-BA. Using a CART predictive model of BA versus Non-BA (significant factors: gamma-
glutamyl transpeptidase, acholic stools, weight), the receiver operating characteristic area
under the curve (ROC AUC) was 0.83. Twelve percent of BA infants were misclassified as
Non-BA; 17% of Non-BA infants were misclassified as BA. Stepwise logistic regression
identified seven factors in a predictive model (ROC AUC 0.89). Using this model, a predicted
probability of >0.8 (n = 357) yielded an 81% true positive rate for BA; <0.2 (n = 120) yielded
an 11% false negative rate.
Conclusion
Despite the relatively good accuracy of our optimized prediction models, the high precision
required for differentiating BA from Non-BA was not achieved. Accurate identification of BA
in infants with neonatal cholestasis requires further evaluation, and BA should not be
excluded based only on presenting clinical features.
Introduction
Neonatal cholestasis is a relatively common clinical issue that presents a complex diagnostic
challenge for clinicians [1]. Cholestasis may not be readily identified at its onset and, as such,
may present late in the course of the underlying disease process. An expansive differential diag-
nosis underlies the condition, which challenges one to prioritize diagnostic evaluations in order
to sort through a complex set of etiologies in a relatively short time [2]. Shotgun approaches to
diagnosis are typically not feasible in infants, while identification of life-threatening and treat-
able causes of cholestasis is a high priority. Newborn screening has the potential to identify
some of the relevant disease processes.
One of the most important and relatively common specific causes of neonatal cholestasis is
biliary atresia (BA). Timely diagnosis of BA is ultimately made by cholangiography at the time
of exploratory laparotomy and histologic assessment of the surgically-removed bile duct rem-
nant. Such timely diagnosis has the potential to improve clinical outcomes, as earlier hepatic
portoenterostomy is associated with longer survival without liver transplantation [3]. Deciding
which infants should undergo surgical exploration is critical. Ideally, one would like to mini-
mize the number of infants who undergo unnecessary surgery, while not missing or delaying
the diagnosis of BA. There is no universal consensus on the sequential steps to be taken in the
diagnostic evaluation of neonatal cholestasis from the time of presentation leading up to
exploratory surgery.
The Childhood Liver Disease Research Network (ChiLDReN), a National Institutes of
Health-funded consortium, has conducted a prospective longitudinal study of 875 infants
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presenting with neonatal cholestasis at 15 clinical sites in the United States and Canada over
an 11-year period. Data collected included details of the presenting clinical features, demo-
graphics, physical findings, laboratory values, and gallbladder sonography results that are typi-
cally available in routine clinical practice. Using these data, the objective of this study was to
determine the predictive value for BA of typical testing performed in the evaluation of chole-
static infants prior to the decision for invasive testing (e.g., liver biopsy, cholangiography,
exploratory laparotomy). A secondary goal was to develop a diagnostic algorithm to help guide
the clinician’s decision-making for invasive testing.
Materials and methods
Study population
Between April 2004 and February 2014, infants presenting with neonatal cholestasis were
enrolled in a prospective observational study of infants with cholestasis (PROBE: https://
clinicaltrials.gov/ct2/show/NCT00061828, conducted by ChiLDReN). Written informed con-
sent was obtained from the study participants’ parents or guardians, and the protocol was car-
ried out under institutional review board (IRB) approval. Given the age of the participants,
assent was not feasible. The IRB at each participating institution has approved PROBE (S1
Table). Inclusion criteria were: 1) age180 days at presentation to a ChiLDReN center; and 2)
serum direct or conjugated bilirubin >20% of total bilirubin (TB) and2mg/dl. The PROBE
protocol permitted the use of laboratory studies drawn prior to enrollment (“presentation”) to
be used for inclusion criteria. Exclusion criteria were: 1) acute liver failure; 2) previous hepato-
biliary surgery; 3) bacterial or fungal sepsis; 4) hypoxia, shock, or ischemic hepatopathy; 5)
malignancy; 6) primary hemolytic disease; 7) drug or total parenteral nutrition-associated cho-
lestasis; 8) extracorporeal membrane oxygenation (ECMO)-associated cholestasis; or 9) birth
weight <1500g in an infant who did not have BA. Presenting clinical features (including stool
color), demographics, physical findings, laboratory data, and gallbladder sonography findings
were collected prospectively and recorded prior to the ultimate assignment of a clinical diag-
nosis. Evaluations of neonatal cholestasis were not prescribed and were according to local
practice and conducted at local facilities.
Not all participants enrolled in PROBE were included in this analysis of predictors of BA.
Participants were included only if they had laboratory studies indicating direct/conjugated
hyperbilirubinemia that were performed at the time of “presentation” to the ChiLDReN clini-
cal site. Inclusion in the BA cohort (Group 1) for this analysis required either the performance
of a biliary drainage procedure for BA or exploratory surgery with the finding of an atretic
extrahepatic bile duct by either inspection or attempted cholangiography. BA could not be
definitively “confirmed” in infants who presented “late” in the clinical course and in whom cli-
nicians determined that laparotomy or laparoscopy would not benefit the child or alter man-
agement. Inclusion in the Non-BA cohort (Group 2) required the identification of a specific
alternative etiology for their cholestasis or cholangiography that excluded BA. For an infant
with the clinical diagnosis of idiopathic neonatal hepatitis (INH) or idiopathic cholestasis (IC)
to be included in this analysis, resolution of cholestasis was required as defined by a subse-
quent TB <1.0 mg/dL at>120 days of age (without hepatic portoenterostomy). INH was
defined as neonatal cholestasis in which histologic evidence of giant cell hepatitis was present
on liver biopsy and for whom no other etiology was confirmed. IC was defined as neonatal
cholestasis that resolved in an infant who did not undergo liver biopsy or did not have giant
cell hepatitis on a liver biopsy, and for whom no other etiology was confirmed. The outcome
variable for this study is a confirmed study definition meeting diagnosis of BA or Non-BA
(i.e., Group 1 vs. Group 2).
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Candidate predictors
Twenty-two variables collected at the time of the first evaluation at the ChiLDReN center were
considered as candidate predictors, including age at disease onset and first evaluation, sex,
race, ethnicity, anthropometrics (weight z-score, height z-score, head circumference z-score),
palpable liver (including number of centimeters below the costal margin at the midclavicular
line), palpable spleen, acholic stools, Alagille “syndromic” facial features, serum TB (defined as
conjugated + unconjugated when total not measured), conjugated/direct bilirubin, alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP),
gamma-glutamyl transpeptidase (GGTP), albumin, platelet count, cholesterol, and gallbladder
sonography (presence or absence of the gallbladder, “small” gallbladder equated with pres-
ence). Age at first evaluation was defined as the earliest date among dates of study informed
consent, diagnosis, or surgery; age at disease onset was defined as the earliest age at which
there was caregiver reported icterus of eyes or skin, darkening of urine, or white/pale stools in
the initial history case report form.
Statistical analysis
Descriptive statistics for the characteristics listed above were provided for BA and Non-BA
subjects included in the model development and those not included (Group 3 = BA not
included and Group 4 = Non-BA not included). Differences between Groups 1 and 2 were
assessed using two sample t-tests for the continuous parameters. Variables with skewed distri-
butions were analyzed after first applying a log transformation, with the accompanying
descriptive statistics reported on the original scale. Categorical variables were assessed using a
Chi-Square test or Fisher’s exact test, where cell size(s) were5 participants.
Model development
Two types of model were used to find the best prediction models: a hierarchical classification
and regression tree (CART) and a logistic regression model [4]. All 22 factors mentioned
above were considered by both approaches, regardless of whether or not they obtained statisti-
cal significance in the univariate setting. CART analysis recursively partitions observations to
define the optimum cutoff point for continuous predictors and identifies homogeneous groups
having the largest difference in the outcome variable (minimum misclassification error rate).
Each partition is a binary split based on a single independent variable. This process results in a
classification rule with the optimum cut point for continuous variables and is represented as a
tree. Once the full tree was grown, a pruning algorithm was run to avoid over-fitting. In the
pruning process, the chi-square statistic for 2x2 contingency tables was calculated for each
split. Using a pre-selected alpha level (p = 0.10), nodes whose chi-square values–as well as the
chi-square values of subsequent splits–did not exceed the predetermined threshold were
pruned.
A logistic regression prediction model was constructed using a forward stepwise hierar-
chical approach, with higher than standard p value, α = 0.10 [5–7]. To avoid losing study
sample due to missing data, a sequential regression imputation method was used to impute
missing values [8]. Only one randomly selected imputed data set was used for model devel-
opment [9]. To define appropriate transformation of continuous variables, we used penal-
ized-spline functions to explore the potential nonlinear effect of potential continuous
predictors [10]. Potential interaction effects identified through CART analysis were con-
sidered in the model development process. The final model consists of only variables main-
taining a 0.10 level of significance.
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Model evaluation
The ability of the multivariate model to correctly classify patients into the dichotomous disease
classification (BA vs. Non-BA) was determined by assessing the area under the receiver operat-
ing characteristic (ROC) curve (AUC), where larger values on the 0–1 scale indicate greater
concordance between the predicted and observed disease groups. Reapplying the model to our
data, we further evaluated the disease misclassification rates at what are considered more
definitive predicted probability thresholds.
The CART analysis was performed using R (version 3.2.2) software. Data imputation and
all other analyses were conducted using SAS (version 9.3)[4].
Results
During the study period, 875 infants with neonatal cholestasis were enrolled in PROBE. Strict
criteria for BA and Non-BA inclusion were used in this analysis to increase the confidence for
the predictive value of variables tested. Thus, 401 infants (Group 1) met criteria for the study
definition of BA; 102 participants were classified clinically as BA by the study site, but after
review of laboratory and operative data at presentation, these patients did not meet the strict
study definition of BA and were excluded from analysis (Group 3: 58 excluded for lack of labo-
ratory data at presentation and 44 for lack of operative demonstration of BA). Groups 1 and 3
were generally similar, except for a skewing of data to a “late” presentation in Group 3, which
likely accounted for the decision to not proceed with hepatic portoenterostomy, thereby
excluding those infants from Group 1 (S2 Table).
There were 259 of 372 infants enrolled in PROBE who did not have a clinical diagnosis of
BA and met study criteria for Non-BA (Group 2). There were 113 infants (Group 4) with a
clinical diagnosis of Non-BA excluded from analysis for potentially more than one reason,
including: 1) inability to definitively exclude BA because, despite having a clinical diagnosis of
indeterminate/IC, INH, choledochal cyst, or “other”, either TB was still elevated (>1 mg/dL)
beyond 120 days of age and/or there was no cholangiographic evidence of bile duct patency; 2)
laboratory data were not available at presentation; and 3) laboratory data at presentation did
not meet PROBE entry criteria. Groups 2 and 4 were similar (S3 Table). The clinical phenotype
in Group 4 may have been milder, with less apparent hepatomegaly and lower biochemical
markers of liver disease (TB, direct bilirubin, conjugated bilirubin, ALT, and AST).
Diagnoses in the 259 Non-BA infants who met study criteria (Group 2) included IC
(n = 72), INH (n = 61), alpha-1 antitrypsin deficiency (n = 31), Alagille syndrome (n = 28),
panhypopituitarism (n = 12), cytomegalovirus infection (n = 10), bile duct paucity (n = 10),
progressive familial intrahepatic cholestasis (n = 8), cystic fibrosis (n = 6), mitochondrial dis-
ease (n = 6), bile acid synthesis defect (n = 5), and other (n = 8; 1 each for hemophagocytic
lymphohistiocytosis, hereditary spherocytosis, neonatal ascites, Caroli’s disease, perinatal scle-
rosing cholangitis, porphyria, hyperinsulinism, and duplicate gall bladder). The demographics,
salient clinical features, and laboratory values of the BA and Non-BA groups obtained at pre-
sentation at the ChiLDReN sites are displayed in Table 1.
Univariate analysis identified 13 variables (Table 1), which were significantly different (in
bold) between BA and Non-BA (Group 1 vs. Group 2), including age at disease onset, stool
color, sex, facial features, weight z-score, length z-score, head circumference z-score, centime-
ters of liver palpable below the costal margin, palpable spleen, GGTP, albumin, platelet count,
and gallbladder sonography. Infants with BA were more likely to have acholic stools, to be
female, to be younger at disease onset, have greater z-score growth parameters, have normal
facial features, more significant hepatosplenomegaly, a higher GGTP, albumin, and platelet
count, and a sonographically absent gallbladder.
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Table 1. Comparison of clinical information at presentation between infants with and without BA.
Variable Group 1 (BA Included) % or Mean (SD) N = 401 Group (Non-BA Included) % or Mean (SD) N = 259 p-value
Race 0.130
White 244 (63%) 156 (61.2%)
Black 61 (15.8%) 51 (20%)
Asian 36 (9.3%) 13 (5.1%)
Other 46 (11.9%) 35 (13.7%)
Sex <0.001
Male 191 (47.6%) 164 (63.3%)
Female 210 (52.4%) 95 (36.7%)
Ethnicity 0.146
Hispanic 92 (23%) 60 (23.3%)
Non-Hispanic 308 (77%) 197 (76.7%)
Age at First Evaluation (Days) N = 401 N = 259 0.176
63.5 (30.9) 60 (33.3)
Age at Disease Onset (Days) N = 401 N = 259 <0.001
12.8 (18.5) 18.7 (22.1)
Weight (kg) N = 398 N = 257 <0.001
4.5 (0.9) 4.1 (1.1)
Length (cm) N = 381 N = 252 <0.001
55.5 (4) 54.3 (4.3)
Head Circumference (cm) N = 336 N = 215 0.015
37.6 (2.2) 37.1 (2.6)
Weight Z-Score N = 398 N = 257 <0.001
-1 (1) -1.5 (1.2)
Length Z-Score N = 381 N = 252 <0.001
-0.8 (1.5) -1.4 (1.5)
Head Circumference Z-Score N = 336 N = 215 0.026
-1.1 (1.6) -1.4 (1.2)
Acholic Stools <0.001
Absent 69 (17.6%) 165 (66%)
Present 322 (82.4%) 85 (34%)
Acholic Stools (3 Levels) <0.001
Normal 69 (17.6%) 165 (66%)
White or Gray 184 (47.1%) 30 (12%)
Pale 138 (35.3%) 55 (22%)
Facial Features <0.001
Normal 380 (95.2%) 207 (81.2%)
Abnormal 19 (4.8%) 48 (18.8%)
Liver Edge Palpable 0.004
Not Palpable 26 (7.3%) 34 (14.5%)
Palpable 332 (92.7%) 201 (85.5%)
Liver Edge Below Costal Margin (cm) N = 334 N = 202 <0.001
3.3 (1.6) 2.5 (1.4)
Spleen Palpable 0.018
Not Palpable 188 (50%) 149 (59.6%)
Palpable 188 (50%) 101 (40.4%)
Direct Baseline Bilirubin (mg/dL) N = 239 N = 162 0.335
5.7 (2.2) 5.8 (3.2)
(Continued )
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We used a hierarchical CART analysis to create an algorithm that could distinguish BA
from Non-BA. In this approach, the population was segregated into either BA or Non-BA in a
stepwise manner based on the single most predictive variable, using a threshold value derived
empirically from the observed data. After this initial segregation, each newly-created sub-pop-
ulation was again evaluated using the most predictive variable that was redefined for this new
subset of the population. In this manner, the predictive power of each variable was maximized
at each step. The process of segregation and reanalysis was continued until there was no fur-
ther improvement in the overall predictive power for the population. The results of this analy-
sis are shown in Fig 1.
If the initial discriminator was a GGTP of 204 IU/L, those with lower levels were unlikely to
have BA (40 [21%] out of 193 infants). In those with GGTP204 IU/L and acholic stools, BA
was likely (303 out of 467 infants). Further discrimination was achieved by incorporating
weight z-score. Overall, the predictive capacity for this model was somewhat worse than the
logistic regression modeling, with an AUC for the ROC of 0.831. When the three-variable
CART analysis was utilized, 12% of infants categorized as Non-BA (n = 247) were misclassified
and had BA. Conversely, 17.5% of infants categorized as BA (n = 415) were misclassified and
did not have BA.
The best logistic regression model selected included nine predictors: sex, acholic stools,
normal facial features, ALT, GGTP, age at disease onset, weight z-score, palpable liver below
Table 1. (Continued)
Variable Group 1 (BA Included) % or Mean (SD) N = 401 Group (Non-BA Included) % or Mean (SD) N = 259 p-value
Conjugated Baseline Bilirubin (mg/dL) N = 215 N = 121 0.871
4.3 (1.6) 4.6 (2.6)
Total Baseline Bilirubin (mg/dL) N = 401 N = 259 0.979
8.3 (3.1) 8.6 (4.3)
AST (u/L) N = 397 N = 254 0.304
232.1 (206.4) 284.2 (347.7)
ALT (u/L) N = 400 N = 255 0.230
154.7 (124.3) 190.7 (232.5)
Albumin (g/dL) N = 391 N = 246 0.006
3.6 (0.5) 3.5 (0.6)
GGTP (u/L) N = 379 N = 238 <0.001
711.9 (537.5) 299 (380.5)
Platelets (103/ mm3) N = 380 N = 243 0.022
445.2 (180.2) 419.7 (197.3)
Alkaline Phosphatase (IU/L) N = 395 N = 254 0.230
568.6 (320.7) 572.1 (252.1)
Total Cholesterol (mg/dL) N = 33 N = 54 0.925
184.2 (61.3) 190.6 (82.3)
Gallbladder <0.001
Absent 125 (39.9%) 13 (6.5%)
Present 5 (1.6%) 1 (1.4%)
Present (Small) 142 (45.4%) 81 (40.7%)
Normal 41 (13.1%) 105 (52.8%)
Gallbladder (Absent vs. Present) <0.001
Absent 125 (39.9%) 13 (6.5%)
Present 188 (60.1%) 186 (93.5%)
https://doi.org/10.1371/journal.pone.0176275.t001
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the costal margin, and a sonographically absent gallbladder, which were associated with a diag-
nosis of BA (Table 2).
Model discriminating ability was assessed by the ROC curve. Larger values on the 0–1 scale
indicated a better predictive model. The final model yielded an AUC for the ROC analysis of
0.892 (Fig 2).
If all 22 candidate predictor features were incorporated into the model, the AUC of the
ROC increased marginally to 0.898. Based upon the final model [logit(p) = -0.367–0.011Age
at Onset (Days) + 0.305Weight Z-Score + 0.320Liver Below Costal Margin—0.002ALT(IU/
L) + 0.002GGTP (IU/L)—0.312Male + 0.252Pale Stools + 1.061White/Gray Stools—
0.755Abnormal Facial Features—0.820Present Gallbladder], a predicted probability of BA
was calculated, with 1 indicating the highest chance (100%) of being BA, and 0 being the lowest
(0%). The distribution of predicted probabilities for BA and actual study diagnoses of BA and
Non-BA are displayed in Fig 3.
Three-hundred fifty-seven infants had a predicted probability >0.8, of whom 290 had BA
(81.2%). Of the 67 remaining Non-BA infants (19%) with a predicted probability of>0.8, 12
had alpha-1 antitrypsin deficiency, and 10 had Alagille syndrome (Table 3). One-hundred
Fig 1. Hierarchical CART analysis of the prediction of BA. A pruned model is shown that uses GGTP level
(cut-off 203.5 IU/L), acholic stools, and wt z-score (cut-off -1.28) to segregate BA from Non-BA as indicated.
https://doi.org/10.1371/journal.pone.0176275.g001
Table 2. Multivariate logistic regression analysis of factors predicting BA.
Variable β Odds Ratio 95% Confidence Interval p-value
Intercept -0.367
Age at Onset (Days) -0.011 0.989 (0.98, 1) 0.0514
Weight Z-Score 0.305 1.357 (1.11, 1.67) 0.003
Liver Below Costal Margin (cm) 0.320 1.377 (1.19, 1.60) <0.0001
ALT (IU/L) -0.002 0.998 (0.997, 1) 0.0265
GGTP(IU/L) 0.002 1.002 (1.001, 1.002) <0.0001
Sex: Male vs. Female -0.312 0.540 (0.35, 0.83) 0.0049
Acholic Stools: <0.0001
Pale vs. Normal 0.252 4.775 (2.9, 7.88)
White/Gray vs. Normal 1.061 10.725 (6.17, 18.66)
Facial Features: Abnormal vs. Normal -0.755 0.221 (0.10, 0.48) 0.0001
Gallbladder: Present vs. Absent -0.820 0.194 (0.11, 0.35) <0.0001
https://doi.org/10.1371/journal.pone.0176275.t002
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thirty-six infants had a predicted probability of<0.2, of whom 120 had Non-BA (88.2%). Six-
teen infants (12%) with scores<0.2 had BA and were evaluated at mean of 63 days of age;
most had normally pigmented stools and gallbladder that was present. One-hundred sixty-
seven infants had intermediate predicted probability scores between 0.2 and 0.8.
Discussion
The quest for finding clinical and laboratory features that distinguish BA from other causes of
neonatal cholestasis has been ongoing for over 50 years [11–20]. Early investigations of over
800 infants in five separate reports from Boston, Toronto, London, Houston, and Bicêtre dem-
onstrated a difficulty in clinically distinguishing BA from intrahepatic cholestasis in a signifi-
cant number of infants [11–15]. Infants with BA more frequently had acholic stools, had less
failure to thrive, and had more pronounced elevation in biochemical markers of bile duct and
canalicular injury, although these features were not uniformly discriminative. More recent
reports have added radiologic and histologic features to the investigative paradigm [17–19].
Most of these studies have been single or two-center studies and retrospective in nature.
The current analysis is based on data obtained in a large, truly multi-centered prospective
study, which was particularly rigorous with regard to the study definition of BA and Non-BA
and with the application of advanced statistical modeling methods. The purpose of the current
study was to attempt to develop a diagnostic algorithm that could distinguish between BA and
Non-BA using non-invasive parameters that were typically obtained during initial clinical
Fig 2. Receiver operator curve analysis of a multivariate model to predict the diagnosis of BA. The
blue solid line is for the final nine-level model. The rest of the curves indicate AUC for a series of models
obtained in the stepwise selection procedure. In stepwise order: intercept only, acholic stools, GGTP,
gallbladder absence, absence of abnormal facial features, centimeters of liver palpable below the costal
margin, weight z-score, sex, ALT, and age of disease onset.
https://doi.org/10.1371/journal.pone.0176275.g002
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evaluation of cholestatic infants. An effective algorithm might serve as a guide to physicians as
to whether invasive procedures, such as liver biopsy and exploratory laparotomy, are war-
ranted. The three variables in the CART analysis (serum GGTP, acholic stools, and weight z-
score) that were statistically derived to achieve the best prediction of BA are simple, mostly
objective, and readily available early in the course of the evaluation of cholestasis. Accurate
classification of the stool pigmentation is the only somewhat subjective parameter in this algo-
rithm [21]; however, recent simple smartphone technology may overcome this [22]. The pre-
dicted probability model that was developed achieved accurate diagnosis of BA in 290 out of
357 cases (81%) when the predictive probability was >0.8. Accuracy in these cases might be
enhanced if alpha-1 antitrypsin levels and phenotype were readily available, and if features of
Alagille syndrome were carefully assessed. One could argue that, for the infants with a predic-
tive probability of>0.8 who had negative diagnostic testing for alpha-1 antitrypsin deficiency
and Alagille syndrome, the next logical step would be exploratory laparotomy, and one might
defer liver biopsy. An accurate diagnosis of Non-BA was predicted in 120 of 136 cases (88%)
when the predicted probability was <0.2. Conversely, an unsettling number of these infants
had BA, whose diagnosis would be delayed or missed if one relied solely on these presenting
clinical features to “exclude” BA. In addition, a significant number of infants had intermediate
predicted probability scores between 0.2 and 0.8 and could not be classified as either BA or
Non-BA.
It is clear from the current detailed analysis that clinicians should be very cautious about
either diagnosing or excluding BA on the basis of presenting clinical features in infants with
Fig 3. Logistic regression model of predicted probability of BA. Based upon a nine-feature model, a
predicted probability of BA was calculated for each participant, with increased probability of BA as the score
increased from 0 to 1. The number of participants with the probability scores is shown on the figure, with those
with BA above the horizontal line and those with Non-BA below the line.
https://doi.org/10.1371/journal.pone.0176275.g003
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Table 3. Demographics, clinical, and laboratory profile of infants with BA predicted probability >0.8 or <0.2 (BA vs. Non-BA).
Predicted Probability Parameter Group 1 (BA) Group 2 (Non-BA) Overall
N Mean (SD) or % N Mean (SD) or % N Mean (SD) or %
0.80 Age at First Evaluation (Days) 290 64.6 (31.2) 67 60.6 (36.6) 357 63.9 (32.3)
Age at Disease Onset (Days) 11.8 (17.2) 15.7 (22.1) 12.5 (18.3)
Weight Z-Scores -0.8 (1.0) -1.3 (1.0) -0.9 (1.0)
Liver Edge Below Costal Margin (cm) 3.4 (1.7) 2.6 (1.5) 3.2 (1.7)
ALT 155 (111) 191 (169) 162 (124)
GGTP 810 (566) 478 (543) 748 (576)
Sex
Male 126 43.5% 39 58.2% 165 46.2%
Female 164 56.6% 28 41.8% 192 53.8%
Acholic Stools
Normal 9 3.1% 4 6.0% 13 3.6%
White or Gray 137 47.2% 7 10.5% 144 40.3%
Pale 144 49.7% 56 83.6% 200 56.0%
Facial Features
Normal 276 95.2% 54 80.6% 330 92.4%
Dysmorphic 14 4.8% 13 19.4% 27 7.6%
Gallbladder
Absent 142 49.0% 11 16.4% 153 42.9%
Present 148 51.0% 56 83.6% 204 57.1%
Diagnosis
BA 285 98.3% 0 0 285 79.8%
Alpha1-Antitrypsin Deficiency 0 0 12 17.9% 12 3.4%
Hereditary Fructose Intolerance 0 0 1 1.5% 1 0.3%
Cystic Fibrosis 0 0 1 1.5% 1 0.3%
PFIC 1, 2, or 3 0 0 1 1.5% 1 0.3%
Alagille Syndrome 1 0.3% 10 14.9% 11 3.1%
Operable-Extrahepatic BA and Choledochal Cyst 2 0.7% 0 0 2 0.6%
INH 0 0 15 22.4% 15 4.2%
Cholestasis, Indeterminate 0 0 18 26.9% 18 5.0%
Other 1 0.3% 8 11.9% 9 2.5%
Choledochal Cyst 1 0.3% 1 1.5% 2 1.5%
0.20 Age at First Evaluation (Days) 16 62.8 (30.8) 120 56.7 (30.3) 136 57.4 (30.3)
Age at Disease Onset (Days) 29.0 (31.4) 22.7 (23.2) 23.4 (24.3)
Weight Z-Scores -1.8 (1.1) -1.8 (1.1) -1.8 (1.1)
Liver Edge Below Costal Margin (cm) 1.9 (1.5) 1.9 (1.1) 1.9 (1.1)
ALT 199 (202) 194 (285) 194 (276)
GGTP 289 (174) 182 (183) 194 (185)
Sex
Male 6 37.5% 84 70.0% 90 66.2%
Female 10 62.5% 36 30.0% 46 33.8%
Acholic Stools
Normal 15 93.8% 119 99.2% 134 98.5%
White or Gray 1 6.3% 1 0.8% 2 1.5%
Pale 0 0 0 0 0 0
Facial Features
Normal 15 93.8% 95 79.2% 110 80.9%
Dysmorphic 1 6.3% 25 20.8% 26 19.1%
Gallbladder
Absent 1 6.3% 2 1.7% 3 2.2%
Present 15 93.8% 118 98.3% 133 97.8%
Diagnosis
BA 12 75.0% 0 0 12 8.8%
Alpha1-Antitrypsin Deficiency 0 0 9 7.5% 9 6.6%
Storage Diseases 1 6.3% 0 0 1 0.7%
Cystic Fibrosis 0 0 1 0.8% 1 0.7%
PFIC 1, 2, or 3 0 0 2 1.7% 2 1.5%
Alagille Syndrome 1 6.3% 5 4.2% 6 4.4%
Bile Acid Synthetic Disorder 0 0 1 0.8% 1 0.7%
INH 0 0 32 26.7% 32 23.5%
Cholestasis, Indeterminate 0 0 36 30.0% 36 26.5%
Other 0 0 28 23.3% 28 20.6%
Hepatitis Due to CMV 0 0 6 5.0% 6 4.4%
Choledochal Cyst 2 12.5% 0 0 2 1.5%
https://doi.org/10.1371/journal.pone.0176275.t003
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cholestasis. Family history is typically noninformative, but in selected circumstances can direct
investigations toward specific inherited disorders like Alagille syndrome or familial intrahepa-
tic cholestasis. Additional diagnostic investigations are typically warranted, and noninvasive
approaches are often the first to be considered [23]. In the current study, only the presence of
gallbladder was considered on ultrasonography. More detailed evaluation for the triangular
cord sign, gallbladder wall characteristics, and hepatic subcapsular blood flow were not con-
ducted, although may have increased the accuracy of the predictive model [18, 24–26]. Hepa-
tobiliary scintigraphy may be especially useful in excluding BA when intestinal excretion of
radiotracer is demonstrated, although nonexcretion is less helpful since it is observed in BA
and Non-BA [27]. Thus, in 60 of 67 cases where a predictive value of>0.8 erroneously sug-
gested BA, stools were pale or normal; in such infants, hepatobiliary scintigraphy may have
been useful.
The current analysis did not attempt to determine the added value of liver histology in the
predictive algorithm, as the focus was to determine the predictive value of tests performed
prior to subjecting infants to invasive testing. Liver histology can be quite informative in the
evaluation of neonatal cholestasis, although false negative rates are disturbing given the conse-
quences of late or missed diagnosis of BA [28, 29]. In addition, the exposure of infants unnec-
essarily to anesthesia (for liver biopsy, cholangiography, or laparotomy) has become a relevant
issue in light of recent reports of potential long-term neurodevelopmental sequelae of general
anesthesia in young children [30]. Clinicians should consider this issue when deciding about
diagnostic testing that may require general anesthesia, including liver biopsy and endoscopic,
percutaneous, or intraoperative cholangiography.
Conclusions
In conclusion, early accurate diagnosis of BA remains challenging. Clinicians are obliged to cat-
egorically exclude BA in the setting of neonatal cholestasis, since failure to make this diagnosis
has potentially profound adverse consequences. This rigorous prospective analysis of presenting
features in neonatal cholestasis was unable to generate a diagnostic algorithm that yielded suffi-
cient ability to discriminate between BA and Non-BA in all patients. Early referral to a specialist,
with consideration for possible liver biopsy or intraoperative cholangiography, needs to be
entertained as soon as cholestasis is identified. Caution should be exercised in excluding BA
based only on clinical non-invasive features. The identification of an alternative definitive diag-
nosis makes BA unlikely, although the Kasai hepatoportoenterostomy has been performed mis-
takenly in some infants with alternative diagnoses, including cystic fibrosis, alpha-1 antitrypsin
deficiency, and Alagille syndrome [31–35]. Although not necessary for all infants with neonatal
cholestasis, surgical exploration with operative cholangiography and/or pathologic examination
of a bile duct remnant remains the only definitive means of making the diagnosis of BA.
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